DMRADamora Therapeutics, Inc.
Is it safe?
Mostly sound, with a caveat: insiders buying, but heavy debt (CCC) and big price swings.
Insiders were net buyers (+$253K, 90 days to Oct 22, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -99% · now 38% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can DMRA take a bad year?
The deepest fall in DMRA's price history on file is −99%; it is 38% below its high today.
Worst drawdown on file · −38% today
- Annualised volatility
- 342%
Annualised volatility · S&P 500 16% · about 21 times the market's own swing
Details›
- Cash and short-term investments
- $541M
- EBITDA, trailing twelve months
- −$271M
- Operating profit, trailing twelve months
- −$271M
- Annualised volatilitytwo years of daily moves
- 342%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 38%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.